IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael Patrick Murphy et al.

Application No. : 10/568,654

Filed: February 22, 2007

For : MITOQUINONE DERIVATIVES USED AS

MITOCHONDRIALLY TARGETED ANTIOXIDANTS

Examiner : Raymond J. Henley III

Art Unit : 1614

Docket No. : 110199.405USPC Date : June 15, 2010

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Applicants note that reference JP 2002-104922 listed as foreign reference cite no. 3 on the attached citation listing is not written in English. Accordingly, Applicants submit

herewith U.S. Patent No. 6,825,179 listed as cite no. 3, which is in the corresponding patent family and written in English. Applicants submit that U.S. Patent No. 6,825,179 provides the relevancy of JP 2002-104922.

Applicants note that reference JP 2003-520827 listed as foreign reference cite no. 4 on the attached citation listing is not written in English. Accordingly, Applicants submit herewith U.S. Patent No. 6,861,447 listed as cite no. 4, which is in the corresponding patent family and written in English. Applicants submit that U.S. Patent No. 6,861,447 provides the relevancy of JP 2003-520827.

Applicants also note that reference JP 03-074395 listed as foreign reference cite no. 2 is not written in English. Accordingly, Applicants direct the Examiner's attention to the abstract, which is written in English and provides the relevancy of this reference.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants also disclose and wish to have considered the following co-pending application by the same assignee:

| Application No. | Filing Date | Publication No. | Publication Date |
|-----------------|-------------|-----------------|------------------|
| 12/410,318 | 03/24/09 | 2009-0258841 | 10/15/09 |

Supplemental IDS

U.S. Application No.: 10/568,654

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
SEED Intellectual Property Law Group PLLC

/Stephen J. Rosenman/
Stephen J. Rosenman, Ph.D.
Registration No. 43,058

SJR:tt Enclosures:

> Information Disclosure Statement Cited References (15)

701 Fifth Avenue, Suite 5400 Seattle, Washington 98104 Phone: (206) 622-4900 Fax: (206) 682-6031

1620995_1.DOCX